Effect of Different Stages of Chronic Kidney Disease and Renal Replacement Therapies on Oxidant-Antioxidant Balance in Uremic Patients

Table 3

Antioxidative status in the study groups.

	CKD 1	CKD 2	CKD 3	CKD 4	HD	PD	𝑃
SOD (U/mL)	81.89±8.38	68.37±2.45	60.23±6.15	54.29±2.94	49.01±3.03	52.53±4.33	<0.001
CAT (U/mL)	62.75±5.42	57.76±7.25	53.52±8.48	51.22±3.66	47.99±5.90	51.92±5.90	<0.001
GSH-Px (U/mL)	7.71±1.01	6.62±0.50	5.23±0.71	5.01±0.82	3.99±1.39	4.94±1.12	<0.001
GSH-GR (U/mL)	1.72±0.06	1.45±0.11	1.34±0.12	1.07±0.19	0.98±0.19	1.13±0.21	<0.001
Vit E (ng/mL)	0.81±0.06	0.62±0.04	0.43±0.05	0.36±0.01	0.29±0.03	0.36±0.01	<0.001
Fe (𝜇g/dL)	81.44±20.45	74.90±8.53	67.00±10.98	61.42±22.08	59.22±16.39	60.90±19.72	<0.001
Bilirubin (mg/L)	6.37±1.80	5.95±1.96	5.50±1.43	5.00±1.41	4.48±1.68	4.40±1.07	<0.001

SOD: superoxide dismutase; CAT: catalase; GSH-Px: glutathione peroxidase; GSH-GR: glutathione reductase; Vit E: vitamin E; Fe: iron. Data are presented as the mean ± SD. Statistically significant differences between all the groups (𝑃<0.001).